What to know
- SELECT enrolled adults with established cardiovascular disease.
- The observed event difference was 1.5 percentage points.
- Cardiovascular evidence is product- and population-specific.
A cardiovascular outcome is different from weight loss
SELECT tested whether semaglutide reduced major cardiovascular events in a defined high-risk population. This matters because lowering weight or improving a laboratory marker does not automatically demonstrate fewer heart attacks or strokes. A medication can have several indications supported by different evidence. A useful reading keeps the cardiovascular question separate from how much weight someone might lose.
The participants and comparison
The randomized, placebo-controlled trial enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of at least 27, without diabetes. Participants received weekly semaglutide, targeting 2.4 mg, or placebo in addition to usual care. [1] Existing disease was central to eligibility. This was not a trial of young adults with no cardiovascular disease taking medication solely for prevention.
Read both forms of the result
The primary composite endpoint was cardiovascular death, nonfatal heart attack or nonfatal stroke. It occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months. The hazard ratio was 0.80. [1] The observed absolute difference was 1.5 percentage points; “20% lower risk” refers to the relative hazard. Neither expression means 20 out of every 100 treated people avoided an event.
| SELECT finding | Semaglutide | Placebo |
|---|---|---|
| Primary composite event | 6.5% | 8.0% |
| Observed absolute difference | 1.5 percentage points lower | Reference group |
| Population | Established cardiovascular disease; BMI ≥27; no diabetes | Same eligibility |
| Follow-up | Mean 39.8 months | Mean 39.8 months |
Applicability depends on baseline risk
Someone with a different medical history starts from a different risk level. The same relative effect, if it applied, could imply a different absolute benefit. The trial cannot simply supply that missing estimate for every low-risk person. It also does not establish identical effects for another molecule or an unapproved preparation. Ask whether a claim refers to the studied medication and whether the patient resembles those enrolled.
Do not replace the rest of cardiovascular care
Wegovy has a cardiovascular risk-reduction indication for adults with established cardiovascular disease and overweight or obesity. [2] That is a reason for a clinical discussion, not a reason to abandon other indicated care. Medication choice still involves contraindications, tolerability, other conditions and access. Weight-loss research such as STEP 1 answers a different primary question and should not be used as an interchangeable cardiovascular-outcomes trial. [3]
Questions that improve the consultation
Ask the prescriber which health outcome is the treatment priority, what evidence supports it in your circumstances and how progress will be assessed. For an online service, ask whether the team can coordinate with your usual clinician and how records or laboratory results are shared. An advertised weight-loss percentage says little about that coordination. A thoughtful choice considers whether the care model fits the complexity of your health history as well as whether the medication is available at a sustainable cost.
Inspect the language of a benefit claim
A composite endpoint combines several kinds of events. A benefit for the combined endpoint does not automatically establish an equally sized effect for each component, each subgroup or every possible heart-related outcome. Ask which result the advertisement is citing. Also distinguish a prespecified outcome from a later exploratory analysis, especially when a precise mechanism is proposed. It is possible to value a robust clinical result while remaining uncertain about how much each biological pathway contributed. A good explanation keeps that uncertainty visible rather than turning a successful trial into a universal heart-health claim.
Sources
Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician.
